Joshua K. Sabari, MD

Articles

KRAS G12C–Mutated NSCLC: Real-World Implications of Novel Targeted Therapy

December 30th 2022

Closing out their review of treatment options for KRAS G12C–mutated NSCLC, expert oncologists look toward future utilization of novel targeted agents in this setting.

2L KRAS Inhibitors for Patients With KRAS G12C–Mutated NSCLC

December 30th 2022

Centering discussion on KRAS inhibitors and associated clinical trials, Martin Dietrich, MD, PhD, and Joshua Sabari, MD, detail the second-line management of KRAS G12C–mutated non–small cell lung cancer.

Non–Small Cell Lung Cancer: Selecting 1L Therapy for Patients With KRAS G12C Mutations

December 23rd 2022

Key opinion leaders identify the first-line treatment armamentarium for patients with KRAS G12C–mutated non–small cell lung cancer.

Non–Small Cell Lung Cancer: Informing 1L Therapy Selection With Molecular Testing

December 23rd 2022

A brief review of how results from adequate molecular testing may help to inform the first-line management of non–small cell lung cancer.

Treatment Strategies for NSCLC With Concomitant KRAS and p53 Mutations

December 23rd 2022

Before closing out their discussion on IO therapy in non–small cell lung cancer, Melissa Johnson, MD, and Joshua Sabari, MD, identify treatment strategies in the setting of concomitant KRAS/p53 mutation.

Emerging Strategies for the Management of NSCLC With KRAS/STK11/KEAP1 Mutations

December 16th 2022

Shared perspectives on the emerging strategies for the management of non–small cell lung cancer following the identification of KRAS/STK11, or KRAS/KEAP1 mutations.

Overcoming Barriers to Molecular Testing in Non–Small Cell Lung Cancer

December 16th 2022

A comprehensive discussion on how to overcome barriers that may inhibit access to adequate molecular testing in patients with non–small cell lung cancer.

Selecting Optimal Treatment for NSCLC With KRAS/STK11, or KRAS/KEAP1 Mutations

December 16th 2022

Contextualizing treatment selection with the POSEIDEN and CheckMate 9LA clinical trials, experts consider how to select the optimal treatment for patients with concomitant KRAS/STK11, or KRAS/KEAP1–mutated NSCLC.

Addressing Inadequate Molecular Testing in Patients With NSCLC

December 16th 2022

Expert perspectives on course-correcting the management of patients with NSCLC who may not have received adequate molecular profiling in the past.

Dr. Sabari on the Importance of Timely Testing for Uncommon Mutations in NSCLC

December 9th 2022

Joshua K. Sabari, MD, discusses the importance of timely testing for uncommon mutations in non–small cell lung cancer.

Non–Small Cell Lung Cancer: Optimizing the Identification of KRAS G12C Mutations

December 9th 2022

Shared insight on best practices in non–small cell lung cancer management to utilize molecular testing and identify patients harboring KRAS G12C mutations.

POSEIDON Study Post-hoc Analysis: Outcomes in Patients With KRAS/STK11/KEAP1 Mutations

December 9th 2022

A focused review of data from the POSEIDEN post-hoc analysis in patients with concomitant KRAS/STK11, or KRAS/KEAP1–mutated non–small cell lung cancer.

Understanding the Nature of a KRAS G12C Mutation in NSCLC

December 9th 2022

Expert oncologists Martin Dietrich, MD, PhD, and Joshua Sabari, MD, elucidate the emergence of KRAS G12C as a molecular marker in the setting of non–small cell lung cancer.

Is There a Role for IO Therapy in NSCLC With Independent KRAS, STK11, or KEAP1 Mutations?

December 9th 2022

Expert oncologists Melissa Johnson, MD, and Joshua Sabari, MD, discuss the occurrence of individual KRAS, STK11, or KEAP1 mutations in patients with non–small cell lung cancer and if there is a role for immunotherapy in the treatment of these patients.

Closing Out With KRAS and HER2 Advances in NSCLC

January 7th 2022

Josh Sabari, MD; Nicholas C. Rohs, MD; and Balazs Halmos, MD; conclude this series by discussing encouraging data and updates in non–small cell lung cancer treatment for patients who harbor KRAS and HER2 abnormalities.

Shaping the Use of Immunotherapy in the Localized Lung Cancer Setting

January 7th 2022

Thoracic Night Live is devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year. This episode is a review of the clinical advancements in lung cancer treatment throughout 2021. Funding from Daiichi Sankyo/Content Independently Developed by OncLive

Reviewing the Year 2021 in Lung Cancer Treatment

December 22nd 2021

Thoracic Night Live is devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year.

Dr. Sabari on Selecting Between Available ALK inhibitors in ALK+ NSCLC

November 1st 2021

Joshua K. Sabari, MD, discusses selecting between available ALK inhibitors in ALK-positive non–small cell lung cancer.

Circling the Latest With ctDNA in Lung Cancer

June 28th 2021

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, discuss the utility with circulating tumor DNA, intriguing data of which were presented during the 2021 ASCO Annual Meeting.

ASCO 2021 Updates With Neoadjuvant Immunotherapy in NSCLC

June 28th 2021

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, cover the latest results with neoadjuvant immunotherapy strategies that were highlighted at the 2021 ASCO Annual Meeting.